Evidence map›Paper›PMID 35847220›Full record

ArticleFrontiers in neurology2022

Quantification of Silent Cerebral Infarction on High-Resolution FLAIR and Cognition in Sickle Cell Anemia.

Hanne Stotesbury, Jamie M Kawadler, Jonathan D Clayden, Dawn E Saunders, Anna M Hood, Melanie Koelbel, Sati Sahota, David C Rees, Olu Wilkey, Mark Layton and 6 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 1 country.

Hanne StotesburyDevelopmental Neurosciences, UCL Great Ormond Street Institute of Child Health, London, United Kingdom.
Jamie M KawadlerDevelopmental Neurosciences, UCL Great Ormond Street Institute of Child Health, London, United Kingdom.
Jonathan D ClaydenDevelopmental Neurosciences, UCL Great Ormond Street Institute of Child Health, London, United Kingdom.
Dawn E SaundersDevelopmental Neurosciences, UCL Great Ormond Street Institute of Child Health, London, United Kingdom.
Anna M HoodDevelopmental Neurosciences, UCL Great Ormond Street Institute of Child Health, London, United Kingdom.
Melanie KoelbelDevelopmental Neurosciences, UCL Great Ormond Street Institute of Child Health, London, United Kingdom.
Sati SahotaDevelopmental Neurosciences, UCL Great Ormond Street Institute of Child Health, London, United Kingdom.
David C ReesKing's College London, London, United Kingdom.
Olu WilkeyNorth Middlesex University Hospital NHS Foundation Trust, London, United Kingdom.
Mark LaytonHaematology, Imperial College Healthcare NHS Foundation Trust, London, United Kingdom.
Maria PelidisDepartment of Haematology and Evelina Children's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
Baba P D InusaDepartment of Haematology and Evelina Children's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
Jo HowardDepartment of Haematology and Evelina Children's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
Subarna ChakravortyKing's College London, London, United Kingdom.
Chris A ClarkDevelopmental Neurosciences, UCL Great Ormond Street Institute of Child Health, London, United Kingdom.
Fenella J KirkhamDevelopmental Neurosciences, UCL Great Ormond Street Institute of Child Health, London, United Kingdom.
Great Ormond Street Hospital · GBGuy's and St Thomas' NHS Foundation Trust · GBUniversity College London · GBKing's College London · GBImperial College Healthcare NHS Trust · GBNorth Middlesex University Hospital NHS Trust · GBUniversity of Manchester · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Research in sickle cell anemia (SCA) has used, with limited race-matched control data, binary categorization of patients according to the presence or absence of silent cerebral infarction (SCI). SCI have primarily been identified using low-resolution MRI, with radiological definitions varying in lesion length and the requirement for abnormality on both fluid attenuated inversion recovery (FLAIR) and T1-weighted images. We aimed to assess the effect of published SCI definitions on global, regional, and lobar lesion metrics and their value in predicting cognition. One hundred and six patients with SCA and 48 controls aged 8-30 years underwent 3T MRI with a high-resolution FLAIR sequence and Wechsler cognitive assessment. Prevalence, number, and volume of lesions were calculated using a semi-automated pipeline for SCI defined as: (1) Liberal: any length (L-SCI); (2) Traditional: >3 mm in greatest dimension (T-SCI); (3) Restrictive; >3 mm in greatest dimension with a corresponding T1-weighted hypo-intensity (R-SCI). Globally, as hypothesized, there were large effects of SCI definition on lesion metrics in patients and controls, with prevalence varying from 24-42% in patients, and 4-23% in controls. However, contrary to hypotheses, there was no effect of any global metric on cognition. Regionally, there was a consistent distribution of SCI in frontal and parietal deep and juxta-cortical regions across definitions and metrics in patients, but no consistent distribution in controls. Effects of regional SCI metrics on cognitive performance were of small magnitude; some were paradoxical. These findings expose the challenges associated with the widespread use of SCI presence as a biomarker of white-matter injury and cognitive dysfunction in cross-sectional high-resolution MRI studies in patients with SCA. The findings indicate that with high-resolution MRI: (1) radiological definitions have a large effect on resulting lesion groups, numbers, and volumes; (2) there is a non-negligible prevalence of lesions in young healthy controls; and (3) at the group-level, there is no cross-sectional association between global lesion metrics and general cognitive impairment irrespective of lesion definition and metric. With high-resolution multi-modal MRI, the dichotomy of presence or absence of SCI does not appear to be a sensitive biomarker for the detection of functionally significant pathology; the search for appropriate endpoints for clinical treatment trials should continue.

Indexed as

anemiacognitionintelligence quotientischemiamagnetic resonance imagingsickle cellsilent cerebral infarctionwhite matter hyperintensities

Identifiers

PMID35847220
PMCPMC9277177
OpenAlexW4285821530

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.